These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Are there two studies that clearly reveal superiority of drug over placebo? Overall JE; Rhoades HM Psychopharmacol Bull; 1984; 20(1):64-7. PubMed ID: 6718653 [No Abstract] [Full Text] [Related]
7. [Decision making in clinical research: a statistical approach]. Lacaine F; Huguier M Gastroenterol Clin Biol; 1980 Nov; 4(11):754-7. PubMed ID: 7461386 [No Abstract] [Full Text] [Related]
8. Methods for the analysis of time to failure data. Prentice RL Prog Clin Biol Res; 1983; 132E():69-79. PubMed ID: 6647490 [No Abstract] [Full Text] [Related]
9. [2 nonparametric statistical tests for small-size samples]. Biebler KE; Jäger B; Voss C Z Arztl Fortbild (Jena); 1986; 80(4):175-7. PubMed ID: 3716471 [No Abstract] [Full Text] [Related]
10. Coding and analysis of spontaneously reported symptoms in clinical trials. Tiplady B; Elton RA; Loudon JB Psychopharmacol Bull; 1983; 19(1):30-2. PubMed ID: 6219417 [No Abstract] [Full Text] [Related]
11. Data analysis I. Some statistical tests for small related samples. Pethybridge RJ J R Nav Med Serv; 1980; 66(2):135-9. PubMed ID: 7431255 [No Abstract] [Full Text] [Related]
12. Randomized clinical trials and research strategy. Simon R Cancer Treat Rep; 1982 May; 66(5):1083-7. PubMed ID: 7083212 [No Abstract] [Full Text] [Related]
13. Antivirals in chronic hepatitis B--problems of small clinical trials. Gregory PB Gastroenterology; 1984 Jan; 86(1):201-4. PubMed ID: 6689662 [No Abstract] [Full Text] [Related]
14. Analysis of preferences in crossover designs. Dunsmore IR Biometrics; 1981 Sep; 37(3):575-8. PubMed ID: 7317560 [No Abstract] [Full Text] [Related]
15. An evaluation of method reporting and use in clinical trials in dermatology. Bigby M; Stern RS; Bigby JA Arch Dermatol; 1985 Nov; 121(11):1394-9. PubMed ID: 4051526 [TBL] [Abstract][Full Text] [Related]
16. [Estimation of sample sizes in four field tables]. Hiller E Z Arztl Fortbild (Jena); 1988; 82(21):1091-3. PubMed ID: 3247793 [No Abstract] [Full Text] [Related]
17. Assessing the impact of ICH E9. Brown D; Day S; Hemmings R; Wright D Pharm Stat; 2008; 7(2):77-87. PubMed ID: 18438957 [TBL] [Abstract][Full Text] [Related]
18. [Controlled therapeutic trials: elaboration of the protocol]. Rodary M Rev Prat; 1983 Apr; 33(19):963-4, 967-8, 971-3. PubMed ID: 6867568 [No Abstract] [Full Text] [Related]
19. Approximately optimal one-parameter boundaries for group sequential trials. Wang SK; Tsiatis AA Biometrics; 1987 Mar; 43(1):193-9. PubMed ID: 3567304 [TBL] [Abstract][Full Text] [Related]